Côme Bommier,Adela Perolla,Ana Zelić Kerep et al.
Côme Bommier et al.
The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3 [0.03%]
关于艾拉纳他班减少给药频率对复发/难治性多发性骨髓瘤患者报告结果的影响：来自MagnetisMM-3研究的结果
Nizar J Bahlis,Ajay K Nooka,Marco DiBonaventura et al.
Nizar J Bahlis et al.
Bridging gaps in clinical trial accessibility and reimbursement for large B-cell lymphoma therapies across Europe [0.03%]
欧洲各类大细胞淋巴瘤的临床试验可及性和报销现状分析
Florence Broussais,Elise Pennings,Natacha Bolanos et al.
Florence Broussais et al.
Correction to "Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia" [0.03%]
对“共价BTKi治疗失败后的补救治疗：华氏巨球蛋白血症临床实践中的一个未满足需求”的勘误通知
[This corrects the article DOI: 10.1002/hem3.70094.]. © 2025 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematolo...
Published Erratum
HemaSphere. 2025 Sep 23;9(9):e70219. DOI:10.1002/hem3.70219 2025
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma [0.03%]
循环肿瘤细胞增多反映多发性骨髓瘤的高增殖和基因组复杂度
Juan-Jose Garces,Benjamin Diamond,Tereza Sevcikova et al.
Juan-Jose Garces et al.
Circulating tumor cells (CTCs) have emerged as a key prognostic factor in newly diagnosed multiple myeloma (NDMM). However, it remains unclear if high CTC counts represent a mere surrogate of tumor burden or might reflect a distinct genomic...
ATMPs prepared under hospital exemption: European Blood Alliance position paper [0.03%]
欧洲血液联盟关于医院豁免条件下制备的ATMPs的立场文件
Dragoslav Domanović,Marc Turner,Christof Jungbauer et al.
Dragoslav Domanović et al.
Editorial
HemaSphere. 2025 Sep 23;9(9):e70215. DOI:10.1002/hem3.70215 2025
Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up [0.03%]
大B细胞淋巴瘤（LBCL）：诊断、治疗和随访的临床实践指南
Catherine Thieblemont,Maria Gomes Da Silva,Sirpa Leppä et al.
Catherine Thieblemont et al.
Large B-cell lymphoma (LBCL) accounts for about one-third of adult lymphoma cases. Diagnosis requires specialized hematopathology laboratories, with immunophenotypic analysis essential for confirming B-cell lineage and identifying variants....
Elevated serum heme oxygenase-1 in pediatric sickle cell disease: Insights from the SickleGenAfrica Network [0.03%]
HO-1升高与儿童镰状细胞病的相关性：来自SickleGenAfrica网络的见解
Anna M Sowa,William Kudzi,Vivian Paintsil et al.
Anna M Sowa et al.
Sickle cell disease (SCD) is characterized by chronic hemolysis, resulting in the release of extracellular heme, which contributes to oxidative stress and inflammation. Heme oxygenase-1 (HO-1), an inducible enzyme that degrades heme into cy...
Freda K Stevenson,Federico Caligaris Cappio
Freda K Stevenson
Editorial
HemaSphere. 2025 Sep 22;9(9):e70223. DOI:10.1002/hem3.70223 2025
Correction to "Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients" [0.03%]
对“597例儿童急性淋巴细胞白血病患者的体外药物反应和分子特征”的勘误通知
[This corrects the article DOI: 10.1002/hem3.70176.]. © 2025 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematolo...
Published Erratum
HemaSphere. 2025 Sep 18;9(9):e70221. DOI:10.1002/hem3.70221 2025